Find a Drug
Advanced Search

Professional

Zocor

Clinical Pharmacology
font size

Clinical Pharmacology

Zocor

N = number of patients in each subgroup. The inverted triangles are point estimates of the relative risk, with their 95% confidence intervals represented as a line. The area of a triangle is proportional to the number of patients with MVE or MCE in the subgroup relative to the number with MVE or MCE, respectively, in the entire study population. The vertical solid line represents a relative risk of one. The vertical dashed line represents the point estimate of relative risk in the entire study population.

Angiographic Studies

In the Multicenter Anti-Atheroma Study, the effect of simvastatin on atherosclerosis was assessed by quantitative coronary angiography in hypercholesterolemic patients with CHD. In this randomized, double-blind, controlled study, patients were treated with simvastatin 20 mg/day or placebo. Angiograms were evaluated at baseline, two and four years. The co-primary study endpoints were mean change per-patient in minimum and mean lumen diameters, indicating focal and diffuse disease, respectively. ZOCOR significantly slowed the progression of lesions as measured in the Year 4 angiogram by both parameters, as well as by change in percent diameter stenosis. In addition, simvastatin significantly decreased the proportion of patients with new lesions and with new total occlusions.

Modifications of Lipid Profiles

Primary Hyperlipidemia (Fredrickson type lla and llb)

ZOCOR has been shown to be effective in reducing total-C and LDL-C in heterozygous familial and non-familial forms of hyperlipidemia and in mixed hyperlipidemia. Maximal to near maximal response is generally achieved within 4-6 weeks and maintained during chronic therapy. ZOCOR consistently and significantly decreased total-C, LDL-C, total-C/HDL-C ratio, and LDL-C/HDL-C ratio; ZOCOR also decreased TG and increased HDL-C (see Table 5).

TABLE 5: Mean Response in Patients with Primary Hyperlipidemia and Combined (mixed) Hyperlipidemia (Mean Percent Change from Baseline After 6 to 24 Weeks)

TREATMENT N TOTAL-C LDL-C HDL-C TG†
Lower Dose Comparative Study ‡ (Mean % Change at Week 6)
  ZOCOR 5 mg q.p.m. 109 -19 -26 10 -12
  ZOCOR 10 mg q.p.m. 110 -23 -30 12 -15
Scandinavian Simvastatin Survival Study§ (Mean % Change at Week 6)
  Placebo 2223 -1 -1 0 -2
  ZOCOR 20 mg q.p.m. 2221 -28 -38 8 -19
Upper Dose Comparative Study || (Mean % Change Averaged at Weeks 18 and 24)
  ZOCOR 40 mg q.p.m. 433 -31 -41 9 -18
  ZOCOR 80 mg q.p.m. ¶ 664 -36 -47 8 -24
Multi-Center Combined Hyperlipidemia Study †† (Mean % Change at Week 6)
  Placebo 125 1 2 3 -4
  ZOCOR 40 mg q.p.m. 123 -25 -29 13 -28
  ZOCOR 80 mg q.p.m. 124 -31 -36 16 -33
† median percent change
‡mean baseline LDL-C 244 mg/dL and median baseline TG 168 mg/dL § mean baseline LDL-C 188 mg/dL and median baseline TG 128 mg/dL
||mean baseline LDL-C 226 mg/dL and median baseline TG 156 mg/Dl
21% and 36% median reduction in TG in patients with TG ≤ 200 mg/dL and TG > 200 mg/dL, respectively. Patients with TG > 350 mg/dL were excluded
†† mean baseline LDL-C 156 mg/dL and median baseline TG 391 mg/dL.

Hypertriglyceridemia (Fredrickson type lV)

Brand Name: Zocor
Generic Name: Simvastatin

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Bookmark this page:

Privacy Policy

Cholesterol Management

Tips to keep it under control.

WebMD Symptom Checker - Start Here Ringworm Slideshow: Watch and Learn
WebMD Resources

Cholesterol GuidelinesCholesterol Guidelines
Think you know all there is to know about cholesterol? Learn the cholesterol guidelines: the good, bad, and that other one. See more WebMD Videos »